RENO, Nev., June 3, 2005 (PRIMEZONE) -- Martin Nutraceuticals Inc. (Pink Sheets:MTNU) - Director of Research and Development, Dr. A.W. Martin, DC, PhD, RNCP, DNM, announced today the results of a clinical study using Oxygenol(tm).
The Martin Nutraceuticals anti-oxidant formula, Oxygenol(tm) is a water soluble, anti-oxidant formula extracted from a particular species of pine bark extract, high in bioflavonoids.
The study was conducted was on Prostatitis, a condition which is characterized by the inflammation of the prostate, with associated symptoms such as urinary dysfunction. It is estimated that one-third of all men over the age of 50 will suffer from this disorder. Prostatitis is believed to be a contributing factor in prostate cancer.
In the study conducted by Dr. A.W. Martin, one group of 10 men over the age of 50 affected by Prostatitis, with an average age of 61, were given 150mg of Oxygenol(tm) daily for 20 days. Another identical group of 10 men also affected by Prostatitis were given placebos, daily for 20 days. There was a significant reduction in swelling and associated urinary symptoms in more than half of the patients using Oxygenol(tm) in the 20-day time frame.
"These concluded clinical studies are validating the science behind the products, as we get ready for our retail product launch," states Dr. Martin.
Oxygenol(tm) will be available on retail shelves shortly.
Forward Looking Statements
This release includes forward-looking statements and projections, made in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The company has made every reasonable effort to ensure that the information and assumptions on which these statements and projections are based are current, reasonable, and complete. However, a variety of factors could cause actual results to differ materially from the projections, anticipated results or other expectations expressed in this release, including, without limitation, the ability to implement and achieve our objectives in the long-range plan; actions by the credit rating agencies; the successful close of our financing transactions; our ability to divest of certain assets; inability to realize anticipated synergies and cost savings associated with restructurings and divestitures on a timely basis; the uncertainties associated with governmental regulation; the uncertainties associated with the outcome of governmental investigations; the outcome of pending litigation including shareholder derivative and class actions; difficulty in integration of the operations of previously acquired companies, and competition. While the company makes these statements and projections in good faith, neither the company nor its management can guarantee that anticipated future results will be achieved. The company assumes no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by the company, whether as a result of new information, future events, or otherwise.